Who are trastuzumab and chemotherapy's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/trastuzumab-and-chemotherapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

trastuzumab and chemotherapy — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

trastuzumab and chemotherapy (trastuzumab and chemotherapy) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HER2-targeted monoclonal antibody + chemotherapy combination. Area: Oncology.

phase 3 HER2-targeted monoclonal antibody + chemotherapy combination HER2 (human epidermal growth factor receptor 2) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

trastuzumab and chemotherapy (trastuzumab and chemotherapy) — Comprehensive Support Project for Oncology Research. Trastuzumab blocks HER2 signaling on cancer cells while chemotherapy drugs kill rapidly dividing cells, combining targeted and cytotoxic approaches.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
trastuzumab and chemotherapy TARGET	trastuzumab and chemotherapy	Comprehensive Support Project for Oncology Research	phase 3	HER2-targeted monoclonal antibody + chemotherapy combination	HER2 (human epidermal growth factor receptor 2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HER2-targeted monoclonal antibody + chemotherapy combination class)

Comprehensive Support Project for Oncology Research · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). trastuzumab and chemotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/trastuzumab-and-chemotherapy. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab